ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 121 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,044,696 | -34.5% | 101,929 | -7.9% | 0.00% | – |
| Q2 2023 | $3,122,649 | +199.7% | 110,693 | +82.7% | 0.00% | – |
| Q1 2023 | $1,042,000 | +110398.4% | 60,601 | +29.4% | 0.00% | – |
| Q4 2022 | $943 | -99.9% | 46,836 | +10.7% | 0.00% | – |
| Q3 2022 | $916,000 | -42.5% | 42,290 | -25.4% | 0.00% | – |
| Q2 2022 | $1,593,000 | -67.3% | 56,700 | -46.3% | 0.00% | -100.0% |
| Q1 2022 | $4,871,000 | +110.9% | 105,579 | +284.2% | 0.00% | – |
| Q4 2021 | $2,310,000 | +38.3% | 27,477 | +9.7% | 0.00% | – |
| Q3 2021 | $1,670,000 | +66.3% | 25,057 | +32.7% | 0.00% | – |
| Q2 2021 | $1,004,000 | +65.4% | 18,876 | +34.9% | 0.00% | – |
| Q1 2021 | $607,000 | -13.4% | 13,988 | +3.7% | 0.00% | – |
| Q4 2020 | $701,000 | +386.8% | 13,490 | +213.9% | 0.00% | – |
| Q3 2020 | $144,000 | -13.8% | 4,297 | +23.6% | 0.00% | – |
| Q2 2020 | $167,000 | – | 3,477 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |